SubsidieMeestersEasy to use, contactless Dual-Mode Ultrasound Technology for high accuracy treatment of Atrial Fibrillation, improving outcomes
Healium aims to revolutionize cardiac ablation with proprietary ultrasound technology for contactless tissue ablation and real-time monitoring, transitioning to clinical studies with €12.75M funding.
Projectdetails
Introduction
Our mission is to radically change the landscape of cardiac ablation. Our products, based on proprietary ultrasound technology, allow contactless tissue ablation with real-time lesion monitoring, bringing Healium to the forefront of the cardiac ablation market.
Team Overview
Our team, backed by scientific and business advisors, includes:
- Dr. Eckhouse, Chairman: A leading medical entrepreneur who has founded over 20 companies and accumulated more than €1B in exits (Ventor for $325M, Synron and Lumenis both IPO > $1B).
- Ran Sela, CEO and co-founder: Over 15 years of medical device development and project management experience.
- Dr. Megel, CTO and co-founder: More than 25 years in ultrasound-based medical devices.
Current Development Phase
Now, we are at the top-risk phase of our development journey: the transition from preclinical to clinical studies.
Funding and Objectives
Leveraging an EC investment of €12.75M, we aim to:
- Demonstrate the efficacy and safety of our product.
- Establish a manufacturing line and regulatory framework.
- Access the market as a self-sustained company.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 11.369.502 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- HEALIUM MEDICAL LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A Novel Handheld Ultrasound Medical Imaging Probe: Prototyping, Initial Validation and Business DevelopmentThe LucidWave Project aims to develop a low-cost, advanced handheld ultrasound probe for improved bedside diagnostics, enhancing medical decision-making and reducing misdiagnosis. | EIC Transition | € 2.427.025 | 2022 | Details |
Closed-Loop and multisEnsing delIvery tool for controlled Laser Ablation of tumorsThe ERC LASER OPTIMAL project aims to develop a closed-loop control platform for laser ablation with fiber optic sensors to enhance precision in cancer treatment and facilitate market readiness. | ERC POC | € 150.000 | 2022 | Details |
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
Laesy Visualisatie 2.0Het project Laesie Visualisatie 2.0 ontwikkelt software voor verbeterde visualisatie van hartweefsel, wat leidt tot efficiëntere behandeling van hartritmestoornissen en lagere gezondheidskosten. | MIT R&D Samenwerking | € 162.190 | 2020 | Details |
A Novel Handheld Ultrasound Medical Imaging Probe: Prototyping, Initial Validation and Business Development
The LucidWave Project aims to develop a low-cost, advanced handheld ultrasound probe for improved bedside diagnostics, enhancing medical decision-making and reducing misdiagnosis.
Closed-Loop and multisEnsing delIvery tool for controlled Laser Ablation of tumors
The ERC LASER OPTIMAL project aims to develop a closed-loop control platform for laser ablation with fiber optic sensors to enhance precision in cancer treatment and facilitate market readiness.
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.
Laesy Visualisatie 2.0
Het project Laesie Visualisatie 2.0 ontwikkelt software voor verbeterde visualisatie van hartweefsel, wat leidt tot efficiëntere behandeling van hartritmestoornissen en lagere gezondheidskosten.